{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:10:06Z","timestamp":1793239806296,"version":"4.5.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1053\/j.akdh.2023.01.003","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T20:54:19Z","timestamp":1682110459000},"page":"245-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon"],"prefix":"10.1053","volume":"30","author":[{"given":"Julie Xia","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.akdh.2023.01.003_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease","volume":"4","author":"Bergmann","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1053\/j.akdh.2023.01.003_bib2","doi-asserted-by":"crossref","first-page":"109637","DOI":"10.1016\/j.cellsig.2020.109637","article-title":"Adhesion GPCRs as a paradigm for understanding polycystin-1 G protein regulation","volume":"72","author":"Maser","year":"2020","journal-title":"Cell Signal"},{"issue":"7479","key":"10.1053\/j.akdh.2023.01.003_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature12833","article-title":"Primary cilia are specialized calcium signalling organelles","volume":"504","author":"Delling","year":"2013","journal-title":"Nature"},{"issue":"9","key":"10.1053\/j.akdh.2023.01.003_bib4","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/ng.2715","article-title":"Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease","volume":"45","author":"Ma","year":"2013","journal-title":"Nat Genet"},{"issue":"8","key":"10.1053\/j.akdh.2023.01.003_bib5","doi-asserted-by":"crossref","first-page":"e54315","DOI":"10.15252\/embr.202154315","article-title":"A cAMP signalosome in primary cilia drives gene expression and kidney cyst formation","volume":"23","author":"Hansen","year":"2022","journal-title":"EMBO Rep"},{"issue":"20","key":"10.1053\/j.akdh.2023.01.003_bib6","doi-asserted-by":"crossref","first-page":"e15058","DOI":"10.14814\/phy2.15058","article-title":"beta3 adrenergic receptor as potential therapeutic target in ADPKD","volume":"9","author":"Schena","year":"2021","journal-title":"Physiol Rep"},{"issue":"10","key":"10.1053\/j.akdh.2023.01.003_bib7","doi-asserted-by":"crossref","first-page":"e21874","DOI":"10.1096\/fj.202100774R","article-title":"Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease","volume":"35","author":"Di Mise","year":"2021","journal-title":"FASEB J"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.003_bib8","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/ki.2011.139","article-title":"Calcimimetics inhibit renal pathology in rodent nephronophthisis","volume":"80","author":"Chen","year":"2011","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.akdh.2023.01.003_bib9","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/ndt\/gfn527","article-title":"Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease","volume":"24","author":"Wang","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1053\/j.akdh.2023.01.003_bib10","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1681\/ASN.2008090927","article-title":"Calcimimetic inhibits late-stage cyst growth in ADPKD","volume":"20","author":"Gattone","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.akdh.2023.01.003_bib11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1681\/ASN.20203110S1496d","article-title":"Small-molecule allosteric activators of long-form PDE4 enzymes suppress cystogenesis in models of ADPKD [Abstract], in ASN Kidney Week Re-imagined, 2020","author":"Henderson","year":"2020","journal-title":"J Am Soc Nephrol: Virtual"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.003_bib12","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1681\/ASN.2021081125","article-title":"Protein kinase A downregulation delays the development and progression of polycystic kidney disease","volume":"33","author":"Wang","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.akdh.2023.01.003_bib13","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1681\/ASN.2021010101","article-title":"Integrative cistromic and transcriptomic analyses identify CREB target genes in cystic renal epithelial cells","volume":"32","author":"Liu","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.003_bib14","doi-asserted-by":"crossref","first-page":"eaaw3593","DOI":"10.1126\/sciadv.aaw3593","article-title":"Activation of P-TEFb by cAMP-PKA signaling in autosomal dominant polycystic kidney disease","volume":"5","author":"Sun","year":"2019","journal-title":"Sci Adv"},{"issue":"10","key":"10.1053\/j.akdh.2023.01.003_bib15","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41419-021-04248-9","article-title":"The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease","volume":"12","author":"Jamadar","year":"2021","journal-title":"Cell Death Dis"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.003_bib16","doi-asserted-by":"crossref","first-page":"e135700","DOI":"10.1172\/jci.insight.135700","article-title":"Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis","volume":"5","author":"Kashyap","year":"2020","journal-title":"JCI Insight"},{"key":"10.1053\/j.akdh.2023.01.003_bib17","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ebiom.2019.08.041","article-title":"Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease","volume":"47","author":"Leonhard","year":"2019","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1053\/j.akdh.2023.01.003_bib18","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1681\/ASN.2015030231","article-title":"2-Deoxy-d-Glucose ameliorates PKD progression","volume":"27","author":"Chiaravalli","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2023.01.003_bib19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bph.14558","article-title":"The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease","volume":"176","author":"Lian","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1053\/j.akdh.2023.01.003_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41420-019-0156-8","article-title":"Low-dose 2-deoxyglucose and metformin synergically inhibit proliferation of human polycystic kidney cells by modulating glucose metabolism","volume":"5","author":"Zhao","year":"2019","journal-title":"Cell Death Discov"},{"issue":"29","key":"10.1053\/j.akdh.2023.01.003_bib21","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.1074\/jbc.RA118.001846","article-title":"A potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector","volume":"293","author":"Yanda","year":"2018","journal-title":"J Biol Chem"},{"issue":"45","key":"10.1053\/j.akdh.2023.01.003_bib22","doi-asserted-by":"crossref","first-page":"17090","DOI":"10.1074\/jbc.RA119.010320","article-title":"Pharmacological reversal of renal cysts from secretion to absorption suggests a potential therapeutic strategy for managing autosomal dominant polycystic kidney disease","volume":"294","author":"Yanda","year":"2019","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1053\/j.akdh.2023.01.003_bib23","doi-asserted-by":"crossref","first-page":"e21987","DOI":"10.1096\/fj.202101315R","article-title":"VX-809 mitigates disease in a mouse model of autosomal dominant polycystic kidney disease bearing the R3277C human mutation","volume":"35","author":"Yanda","year":"2021","journal-title":"FASEB J"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.003_bib24","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1038\/s41467-020-18104-5","article-title":"Cyst growth in ADPKD is prevented by pharmacological and genetic inhibition of TMEM16A in vivo","volume":"11","author":"Cabrita","year":"2020","journal-title":"Nat Commun"},{"issue":"554","key":"10.1053\/j.akdh.2023.01.003_bib25","doi-asserted-by":"crossref","first-page":"eaba3613","DOI":"10.1126\/scitranslmed.aba3613","article-title":"Activation of NRF2 ameliorates oxidative stress and cystogenesis in autosomal dominant polycystic kidney disease","volume":"12","author":"Lu","year":"2020","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.003_bib26","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s42003-021-02730-w","article-title":"Metabolic derangement in polycystic kidney disease mouse models is ameliorated by mitochondrial-targeted antioxidants","volume":"4","author":"Daneshgar","year":"2021","journal-title":"Commun Biol"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.003_bib27","doi-asserted-by":"crossref","first-page":"e22089","DOI":"10.1096\/fj.202101270RR","article-title":"Antioxidant enzyme peroxiredoxin 5 regulates cyst growth and ciliogenesis via modulating Plk1 stability","volume":"36","author":"Agborbesong","year":"2022","journal-title":"FASEB J"},{"issue":"7","key":"10.1053\/j.akdh.2023.01.003_bib28","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1172\/JCI64401","article-title":"Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease","volume":"123","author":"Zhou","year":"2013","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1053\/j.akdh.2023.01.003_bib29","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1172\/JCI90921","article-title":"Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease","volume":"127","author":"Li","year":"2017","journal-title":"J Clin Invest"},{"issue":"14","key":"10.1053\/j.akdh.2023.01.003_bib30","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1093\/hmg\/ddv136","article-title":"Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD","volume":"24","author":"Zhou","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1053\/j.akdh.2023.01.003_bib31","doi-asserted-by":"crossref","first-page":"981963","DOI":"10.3389\/fmolb.2022.981963","article-title":"Emerging therapies for autosomal dominant polycystic kidney disease with a Focus on cAMP signaling","volume":"9","author":"Zhou","year":"2022","journal-title":"Front Mol Biosci"},{"issue":"25","key":"10.1053\/j.akdh.2023.01.003_bib32","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.akdh.2023.01.003_bib33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"20","key":"10.1053\/j.akdh.2023.01.003_bib34","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.akdh.2023.01.003_bib35","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2018.09.016","article-title":"Determinants of urine volume in ADPKD patients using the vasopressin V2 receptor antagonist tolvaptan","volume":"73","author":"Kramers","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.003_bib36","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2215\/CJN.11260821","article-title":"Effects of hydrochlorothiazide and metformin on aquaresis and nephroprotection by a vasopressin V2 receptor antagonist in ADPKD: a randomized crossover trial","volume":"17","author":"Kramers","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.akdh.2023.01.003_bib37","article-title":"Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease (ADPKD): analysis of pivotal clinical trials","author":"Alpers DH","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.003_bib38","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1159\/000500667","article-title":"Effect of a vasopressin V2 receptor antagonist on polycystic kidney disease development in a rat model","volume":"49","author":"Wang","year":"2019","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2023.01.003_bib39","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11095-019-2726-0","article-title":"Comparison of the hepatotoxic potential of two treatments for autosomal-dominant polycystic kidney DiseaseUsing quantitative systems toxicology modeling","volume":"37","author":"Woodhead","year":"2020","journal-title":"Pharm Res (N Y)"},{"issue":"3","key":"10.1053\/j.akdh.2023.01.003_bib40","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2019,5\u2019-cyclic monophosphate","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.003_bib41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.26140","article-title":"Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases","volume":"58","author":"Masyuk","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.003_bib42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1681\/ASN.2013121312","article-title":"Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model","volume":"26","author":"Hopp","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.003_bib43","doi-asserted-by":"crossref","first-page":"e1002777","DOI":"10.1371\/journal.pmed.1002777","article-title":"Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): a randomized, double-blind, placebo-controlled, multicenter trial","volume":"16","author":"Perico","year":"2019","journal-title":"PLoS Med"},{"issue":"9903","key":"10.1053\/j.akdh.2023.01.003_bib44","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"10.1053\/j.akdh.2023.01.003_bib45","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA"},{"issue":"3","key":"10.1053\/j.akdh.2023.01.003_bib46","doi-asserted-by":"crossref","first-page":"F261","DOI":"10.1152\/ajprenal.00345.2014","article-title":"Effects of hydration in rats and mice with polycystic kidney disease","volume":"308","author":"Hopp","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"issue":"8","key":"10.1053\/j.akdh.2023.01.003_bib47","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1681\/ASN.2006030251","article-title":"Increased water intake decreases progression of polycystic kidney disease in the PCK rat","volume":"17","author":"Nagao","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.003_bib48","doi-asserted-by":"crossref","first-page":"e0209186","DOI":"10.1371\/journal.pone.0209186","article-title":"Increased water intake reduces long-term renal and cardiovascular disease progression in experimental polycystic kidney disease","volume":"14","author":"Sagar","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.003_bib49","doi-asserted-by":"crossref","first-page":"e018794","DOI":"10.1136\/bmjopen-2017-018794","article-title":"Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD)","volume":"8","author":"Wong","year":"2018","journal-title":"BMJ Open"},{"issue":"3","key":"10.1053\/j.akdh.2023.01.003_bib50","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.kint.2016.03.020","article-title":"beta3 adrenergic receptor in the kidney may be a new player in sympathetic regulation of renal function","volume":"90","author":"Procino","year":"2016","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.003_bib51","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/hep.29284","article-title":"TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate\/Galphas signaling","volume":"66","author":"Masyuk","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1053\/j.akdh.2023.01.003_bib52","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.kint.2020.02.012","article-title":"The positive effect of selective prostaglandin E2 receptor EP2 and EP4 blockade on cystogenesis in vitro is counteracted by increased kidney inflammation in vivo","volume":"98","author":"Lannoy","year":"2020","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.003_bib53","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1053\/j.gastro.2010.04.010","article-title":"Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD","volume":"139","author":"Gradilone","year":"2010","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.003_bib54","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1681\/ASN.2012050442","article-title":"TRPV4 dysfunction promotes renal cystogenesis in autosomal recessive polycystic kidney disease","volume":"24","author":"Zaika","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.003_bib55","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1038\/s41598-018-23732-5","article-title":"Activation of calcium-sensing receptor increases intracellular calcium and decreases cAMP and mTOR in PKD1 deficient cells","volume":"8","author":"Di Mise","year":"2018","journal-title":"Sci Rep"},{"key":"10.1053\/j.akdh.2023.01.003_bib56","doi-asserted-by":"crossref","first-page":"109497","DOI":"10.1016\/j.cellsig.2019.109497","article-title":"Proliferative signaling by ERBB proteins and RAF\/MEK\/ERK effectors in polycystic kidney disease","volume":"67","author":"Parker","year":"2020","journal-title":"Cell Signal"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.003_bib57","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1046\/j.1523-1755.2003.00232.x","article-title":"Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability","volume":"64","author":"Sweeney","year":"2003","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.003_bib58","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5527\/wjn.v6.i4.188","article-title":"Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease","volume":"6","author":"Sweeney","year":"2017","journal-title":"World J Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2023.01.003_bib59","doi-asserted-by":"crossref","first-page":"C522","DOI":"10.1152\/ajpcell.00163.2010","article-title":"c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation","volume":"301","author":"Elliott","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"issue":"7","key":"10.1053\/j.akdh.2023.01.003_bib60","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1681\/ASN.2007060665","article-title":"Src inhibition ameliorates polycystic kidney disease","volume":"19","author":"Sweeney","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.akdh.2023.01.003_bib61","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1681\/ASN.2016111232","article-title":"Bosutinib versus placebo for autosomal dominant polycystic kidney disease","volume":"28","author":"Tesar","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.akdh.2023.01.003_bib62","doi-asserted-by":"crossref","first-page":"109698","DOI":"10.1016\/j.cellsig.2020.109698","article-title":"Implications of the PAPP-A-IGFBP-IGF-1 pathway in the pathogenesis and treatment of polycystic kidney disease","volume":"73","author":"Kashyap","year":"2020","journal-title":"Cell Signal"},{"key":"10.1053\/j.akdh.2023.01.003_bib63","doi-asserted-by":"crossref","first-page":"109468","DOI":"10.1016\/j.cellsig.2019.109468","article-title":"The PI3K\/Akt\/mTOR pathway in polycystic kidney disease: a complex interaction with polycystins and primary cilium","volume":"66","author":"Margaria","year":"2020","journal-title":"Cell Signal"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.003_bib64","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1440-1797.2007.00811.x","article-title":"Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease","volume":"12","author":"Wahl","year":"2007","journal-title":"Nephrology"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.003_bib65","first-page":"31","article-title":"AKT signaling promotes DNA damage accumulation and proliferation in polycystic kidney disease","volume":"29","author":"Conduit","year":"2020","journal-title":"Hum Mol Genet"},{"issue":"39","key":"10.1053\/j.akdh.2023.01.003_bib66","doi-asserted-by":"crossref","first-page":"40419","DOI":"10.1074\/jbc.M405079200","article-title":"Calcium restriction allows cAMP activation of the B-Raf\/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype","volume":"279","author":"Yamaguchi","year":"2004","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.003_bib67","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1681\/ASN.2014100967","article-title":"Phosphoinositide 3-kinase-C2alpha regulates polycystin-2 ciliary entry and protects against kidney cyst formation","volume":"27","author":"Franco","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.akdh.2023.01.003_bib68","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1093\/ndt\/gfr432","article-title":"The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis","volume":"26","author":"Buchholz","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.akdh.2023.01.003_bib69","doi-asserted-by":"crossref","first-page":"F944","DOI":"10.1152\/ajprenal.00387.2010","article-title":"Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells","volume":"299","author":"Yamaguchi","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.003_bib70","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1002\/hep.25872","article-title":"Cyclic AMP\/PKA-dependent paradoxical activation of Raf\/MEK\/ERK signaling in polycystin-2 defective mice treated with sorafenib","volume":"56","author":"Spirli","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.003_bib71","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1681\/ASN.2004090800","article-title":"Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease","volume":"17","author":"Omori","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.akdh.2023.01.003_bib72","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/hmg\/ddn039","article-title":"Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1","volume":"17","author":"Shibazaki","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.003_bib73","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat Med"},{"issue":"9","key":"10.1053\/j.akdh.2023.01.003_bib74","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1074\/jbc.M806780200","article-title":"Mechanistic insight into control of CFTR by AMPK","volume":"284","author":"Kongsuphol","year":"2009","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1053\/j.akdh.2023.01.003_bib75","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Inoki","year":"2003","journal-title":"Cell"},{"key":"10.1053\/j.akdh.2023.01.003_bib76","doi-asserted-by":"crossref","first-page":"10856","DOI":"10.1038\/ncomms10856","article-title":"AMPK antagonizes hepatic glucagon-stimulated cyclic AMP signalling via phosphorylation-induced activation of cyclic nucleotide phosphodiesterase 4B","volume":"7","author":"Johanns","year":"2016","journal-title":"Nat Commun"},{"issue":"20","key":"10.1053\/j.akdh.2023.01.003_bib77","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1042\/CS20210821","article-title":"Chronic activation of AMP-activated protein kinase leads to early-onset polycystic kidney phenotype","volume":"135","author":"Wilson","year":"2021","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.003_bib78","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1074\/jbc.275.1.223","article-title":"Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I","volume":"275","author":"El-Mir","year":"2000","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.003_bib79","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.003_bib80","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1152\/ajprenal.00298.2021","article-title":"Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model","volume":"322","author":"Pastor-Soler","year":"2022","journal-title":"Am J Physiol Renal Physiol"},{"issue":"10","key":"10.1053\/j.akdh.2023.01.003_bib81","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/hmg\/ddab340","article-title":"Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice","volume":"31","author":"Chang","year":"2022","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1053\/j.akdh.2023.01.003_bib82","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2021.06.013","article-title":"Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)","volume":"100","author":"Perrone","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.003_bib83","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/j.ajkd.2021.06.026","article-title":"Metformin therapy in autosomal dominant polycystic kidney disease: a feasibility study","volume":"79","author":"Brosnahan","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 2","key":"10.1053\/j.akdh.2023.01.003_bib84","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1002\/dmrr.249","article-title":"The mode of action of thiazolidinediones","volume":"18","author":"Hauner","year":"2002","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.003_bib85","doi-asserted-by":"crossref","first-page":"E175","DOI":"10.1152\/ajpendo.00453.2005","article-title":"Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues","volume":"291","author":"LeBrasseur","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1053\/j.akdh.2023.01.003_bib86","doi-asserted-by":"crossref","first-page":"274376","DOI":"10.1155\/2010\/274376","article-title":"Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease","volume":"2010","author":"Blazer-Yost","year":"2010","journal-title":"PPAR Res"},{"issue":"7","key":"10.1053\/j.akdh.2023.01.003_bib87","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/ckj\/sfaa232","article-title":"A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease","volume":"14","author":"Blazer-Yost","year":"2021","journal-title":"Clin Kidney J"},{"issue":"6083","key":"10.1053\/j.akdh.2023.01.003_bib88","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1126\/science.1215327","article-title":"The ancient drug salicylate directly activates AMP-activated protein kinase","volume":"336","author":"Hawley","year":"2012","journal-title":"Science"},{"key":"10.1053\/j.akdh.2023.01.003_bib89","doi-asserted-by":"crossref","first-page":"114213","DOI":"10.1016\/j.bcp.2020.114213","article-title":"Cellular toxicity of the metabolic inhibitor 2-deoxyglucose and associated resistance mechanisms","volume":"182","author":"Laussel","year":"2020","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1053\/j.akdh.2023.01.003_bib90","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1681\/ASN.2015020132","article-title":"Food restriction ameliorates the development of polycystic kidney disease","volume":"27","author":"Warner","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.akdh.2023.01.003_bib91","doi-asserted-by":"crossref","first-page":"F726","DOI":"10.1152\/ajprenal.00551.2015","article-title":"A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease","volume":"310","author":"Kipp","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.003_bib92","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2215\/CJN.16871020","article-title":"Overweight and obesity and progression of ADPKD","volume":"16","author":"Nowak","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2023.01.003_bib93","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease","volume":"29","author":"Nowak","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.003_bib94","doi-asserted-by":"crossref","first-page":"103697","DOI":"10.1016\/j.isci.2021.103697","article-title":"Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease","volume":"25","author":"Hopp","year":"2022","journal-title":"iScience"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.003_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2019.09.012","article-title":"Ketosis ameliorates renal cyst growth in polycystic kidney disease","volume":"30","author":"Torres","year":"2019","journal-title":"Cell Metab"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.003_bib96","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/ckj\/sfab162","article-title":"Ketogenic dietary interventions in autosomal dominant polycystic kidney disease-a retrospective case series study: first insights into feasibility, safety and effects","volume":"15","author":"Strubl","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1053\/j.akdh.2023.01.003_bib97","first-page":"gfac311","article-title":"RESET-PKD: a pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease","author":"Oehm","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1053\/j.akdh.2023.01.003_bib98","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.molmed.2011.06.003","article-title":"mTOR signaling in polycystic kidney disease","volume":"17","author":"Ibraghimov-Beskrovnaya","year":"2011","journal-title":"Trends Mol Med"},{"issue":"5","key":"10.1053\/j.akdh.2023.01.003_bib99","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/ki.2010.457","article-title":"mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression","volume":"79","author":"Huber","year":"2011","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.akdh.2023.01.003_bib100","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.akdh.2023.01.003_bib101","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.akdh.2023.01.003_bib102","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/j.1600-6143.2010.03152.x","article-title":"Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: what is the appropriate serum level?","volume":"10","author":"Canaud","year":"2010","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1053\/j.akdh.2023.01.003_bib103","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1681\/ASN.2012040367","article-title":"Folate-conjugated rapamycin slows progression of polycystic kidney disease","volume":"23","author":"Shillingford","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2023.01.003_bib104","doi-asserted-by":"crossref","first-page":"F395","DOI":"10.1152\/ajprenal.00057.2018","article-title":"Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease","volume":"315","author":"Kipp","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1053\/j.akdh.2023.01.003_bib105","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jconrel.2018.11.019","article-title":"Folate-dactolisib conjugates for targeting tubular cells in polycystic kidneys","volume":"293","author":"Shi","year":"2019","journal-title":"J Control Release"},{"key":"10.1053\/j.akdh.2023.01.003_bib106","doi-asserted-by":"crossref","first-page":"683247","DOI":"10.3389\/fbioe.2021.683247","article-title":"Targeted drug delivery systems for kidney diseases","volume":"9","author":"Huang","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.003_bib107","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0272-6386(98)70072-1","article-title":"Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease","volume":"32","author":"O\u2019Sullivan","year":"1998","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.003_bib108","first-page":"529","article-title":"Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis","volume":"19","author":"Xu","year":"2006","journal-title":"J Nephrol"},{"issue":"12","key":"10.1053\/j.akdh.2023.01.003_bib109","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1681\/ASN.V11122285","article-title":"CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease","volume":"11","author":"Persu","year":"2000","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.akdh.2023.01.003_bib110","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1681\/ASN.2007070828","article-title":"Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease","volume":"19","author":"Yang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.akdh.2023.01.003_bib111","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cellsig.2017.04.001","article-title":"Niclosamide: beyond an antihelminthic drug","volume":"41","author":"Chen","year":"2018","journal-title":"Cell Signal"},{"key":"10.1053\/j.akdh.2023.01.003_bib112","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1471-2369-15-63","article-title":"Hyperuricemia and deterioration of renal function in autosomal dominant polycystic kidney disease","volume":"15","author":"Han","year":"2014","journal-title":"BMC Nephrol"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.003_bib113","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ki.2008.246","article-title":"KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease","volume":"74","author":"Albaqumi","year":"2008","journal-title":"Kidney Int"},{"issue":"11","key":"10.1053\/j.akdh.2023.01.003_bib114","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1097\/01.ASN.0000034220.09301.9C","article-title":"Sulfonylurea-sensitive K(+) transport is involved in Cl(-) secretion and cyst trowth by cultured ADPKD cells","volume":"13","author":"Sullivan","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.003_bib115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/MNH.0000000000000751","article-title":"KCa3.1 in diabetic kidney disease","volume":"31","author":"Huang","year":"2022","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"16","key":"10.1053\/j.akdh.2023.01.003_bib116","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1128\/MCB.24.16.7130-7139.2004","article-title":"Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2","volume":"24","author":"Kobayashi","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.003_bib117","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1128\/MCB.01204-10","article-title":"SCF\/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner","volume":"31","author":"Rada","year":"2011","journal-title":"Mol Cell Biol"},{"issue":"26","key":"10.1053\/j.akdh.2023.01.003_bib118","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.akdh.2023.01.003_bib119","doi-asserted-by":"crossref","first-page":"14395","DOI":"10.1038\/ncomms14395","article-title":"microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism","volume":"8","author":"Hajarnis","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.003_bib120","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1038\/s41467-019-11918-y","article-title":"Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease","volume":"10","author":"Lee","year":"2019","journal-title":"Nat Commun"},{"issue":"24","key":"10.1053\/j.akdh.2023.01.003_bib121","doi-asserted-by":"crossref","first-page":"e00337-17","DOI":"10.1128\/MCB.00337-17","article-title":"Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease","volume":"37","author":"Ishimoto","year":"2017","journal-title":"Mol Cell Biol"},{"issue":"7","key":"10.1053\/j.akdh.2023.01.003_bib122","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nm.2171","article-title":"Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models","volume":"16","author":"Natoli","year":"2010","journal-title":"Nat Med"},{"key":"10.1053\/j.akdh.2023.01.003_bib123","article-title":"Venglustat, a novel glucosylceramide synthase inhibitor, in patients at risk of rapidly progressing ADPKD: primary results of a double-blind, placebo-controlled, phase 2\/3 randomized clinical trial","author":"Gansevoort","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"15","key":"10.1053\/j.akdh.2023.01.003_bib124","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.akdh.2023.01.003_bib125","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.199","article-title":"Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats","volume":"84","author":"Wang","year":"2013","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.003_bib126","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1159\/000368540","article-title":"Inhibition of sodium-glucose cotransporter 2 with dapagliflozin in han: SPRD rats with polycystic kidney disease","volume":"40","author":"Rodriguez","year":"2015","journal-title":"Kidney Blood Press Res"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.003_bib127","doi-asserted-by":"crossref","first-page":"e0125603","DOI":"10.1371\/journal.pone.0125603","article-title":"Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats","volume":"10","author":"Kapoor","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1053\/j.akdh.2023.01.003_bib128","doi-asserted-by":"crossref","first-page":"6382","DOI":"10.1096\/fj.201902901R","article-title":"Pannexin-1 mediates fluid shear stress-sensitive purinergic signaling and cyst growth in polycystic kidney disease","volume":"34","author":"Verschuren","year":"2020","journal-title":"FASEB J"},{"issue":"2","key":"10.1053\/j.akdh.2023.01.003_bib129","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1681\/ASN.V102218","article-title":"ATP release mechanisms in primary cultures of epithelia derived from the cysts of polycystic kidneys","volume":"10","author":"Wilson","year":"1999","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.003_bib130","doi-asserted-by":"crossref","first-page":"F763","DOI":"10.1152\/ajprenal.0337.2000","article-title":"Autocrine extracellular purinergic signaling in epithelial cells derived from polycystic kidneys","volume":"282","author":"Schwiebert","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"issue":"9","key":"10.1053\/j.akdh.2023.01.003_bib131","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1681\/ASN.2010070728","article-title":"Inhibition of the P2X7 receptor reduces cystogenesis in PKD","volume":"22","author":"Chang","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.003_bib132","doi-asserted-by":"crossref","first-page":"F1649","DOI":"10.1152\/ajprenal.00395.2019","article-title":"Knockout of P2rx7 purinergic receptor attenuates cyst growth in a rat model of ARPKD","volume":"317","author":"Arkhipov","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"10.1053\/j.akdh.2023.01.003_bib133","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1681\/ASN.2018010039","article-title":"Lipid peroxidation drives renal cyst growth in vitro through activation of TMEM16A","volume":"30","author":"Schreiber","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"6 Pt 2","key":"10.1053\/j.akdh.2023.01.003_bib134","first-page":"F863","article-title":"Extracellular nucleotide receptor inhibits AVP-stimulated water permeability in inner medullary collecting duct","volume":"269","author":"Kishore","year":"1995","journal-title":"Am J Physiol"},{"issue":"2 Pt 2","key":"10.1053\/j.akdh.2023.01.003_bib135","first-page":"F216","article-title":"Protein kinase C inhibits arginine vasopressin-stimulated cAMP accumulation via a Gi-dependent mechanism","volume":"264","author":"Teitelbaum","year":"1993","journal-title":"Am J Physiol"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.003_bib136","doi-asserted-by":"crossref","first-page":"F1464","DOI":"10.1152\/ajprenal.90542.2008","article-title":"f flow-sensitive, purinergic Cai2+ signaling in human ADPKD cyst epithelial cells","volume":"296","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"10.1053\/j.akdh.2023.01.003_bib137","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11302-007-9072-0","article-title":"Loss of apical monocilia on collecting duct principal cells impairs ATP secretion across the apical cell surface and ATP-dependent and flow-induced calcium signals","volume":"4","author":"Hovater","year":"2008","journal-title":"Purinergic Signal"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.003_bib138","doi-asserted-by":"crossref","first-page":"F1715","DOI":"10.1152\/ajprenal.90311.2008","article-title":"Potential role of purinergic signaling in urinary concentration in inner medulla: insights from P2Y2 receptor gene knockout mice","volume":"295","author":"Zhang","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"issue":"8","key":"10.1053\/j.akdh.2023.01.003_bib139","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ekir.2020.06.002","article-title":"Biological efficacy and safety of niacinamide in patients with ADPKD","volume":"5","author":"El Ters","year":"2020","journal-title":"Kidney Int Rep"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813923000034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813923000034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:39:07Z","timestamp":1757432347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813923000034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":139,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2949813923000034"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2023.01.003","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2023.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}